<DOC>
	<DOC>NCT00417209</DOC>
	<brief_summary>The purpose of this study is to compare the efficacy and the safety Larotaxel administered as single agent every 3 weeks to continuous administration of 5-FU every 3 weeks, in patients with advanced pancreatic cancer (non operable in a curative intent, locally recurrent or metastatic) previously treated with gemcitabine based therapy.</brief_summary>
	<brief_title>Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Advanced (non operable in a curative intent, locally recurrent or metastatic disease) Cytologically or histologically proven epithelial cancer (adenocarcinoma) of the exocrine pancreas. Patient must be previously treated with a systemic gemcitabine based regimen Adequate bone marrow, kidney and liver functions ECOG performance status (PS) of 234. Prior locoregional radiotherapy for pancreatic cancer. Symptomatic brain metastases or leptomeningeal disease. Any serious intercurrent infections, uncontrolled cardiac or gastrointestinal diseases. Other concurrent malignancy Other protocoldefined exclusion/inclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>advanced pancreatic cancer</keyword>
</DOC>